by aaronbiby | Jun 18, 2021
Affiliations: 1. Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany; 2. NIHR-Wellcome Trust, King’s Clinical Research Facility, King’s College London, London, UK; and Department of Neurology, University of California, Los Angeles, Los Angeles...
by aaronbiby | Jun 7, 2021
Objective: Ubrogepant, approved for the acute treatment of migraine, demonstrated efficacy in treating migraine with moderate/severe pain. Clinical guidance recommends treatment when pain is mild, a strategy studied here for ubrogepant. Design and setting: Phase-3,...
by aaronbiby | Jun 7, 2021
Objective: Combining onabotulinumtoxinA with CGRPmAbs can potentially be more effective than each therapy alone for preventing chronic migraine (CM). In the primary analysis cohort, records from 257 adults with CM receiving onabotulinumtoxinA with CGRPmAb showed that...
by aaronbiby | Jun 7, 2021
Objective: To compare rimegepant with placebo in the acute treatment of migraine for pain relief and ability to function normally at early (≤2 hours) and sustained (up to 48 hours) endpoints in pooled data from 3 randomized clinical trials. Design and setting: Three...
Recent Comments